Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Cervical Cancer
Interventions: Colposcopy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Cardiovascular Diseases, Sedentary Behavior
Interventions: Hoosier Sport; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 9 Years to 15 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Allergy and Asthma
Interventions: Not listed
Lead sponsor: Mead Johnson Nutrition; Industry
Eligibility: 3 Years to 7 Years
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colorectal Cancer
Interventions: favezelimab/pembrolizumab, regorafenib, TAS-102; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more

Conditions: Overactive Bladder
Interventions: Vibegron, Placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 75
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more

Conditions: Asthma
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cataract; Eye Disease
Interventions: Novel "Snaps" Eye Shield, Standard Alcon Eye Shield; Device · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Marijuana Abuse
Interventions: MET, MOMENT; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 24 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: Acute Kidney Injury
Interventions: Conventional Foley Catheter(Medline), Accuryn Foley Catheter; Device
Lead sponsor: Dang Tan Phat; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Irvine, California

Conditions: Prader-Willi Syndrome
Interventions: Placebo, Tesomet; Other · Drug
Lead sponsor: Saniona; Industry
Eligibility: 13 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Decision-making tool for coronary artery disease treatment; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Tobacco Use Cessation, Alcohol-related Disorders
Interventions: behavioral counseling plus contingency management; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Newington, Connecticut • West Haven, Connecticut

Conditions: Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions: Rivaroxaban, Warfarin and Enoxaparin; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: CIN-107; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 36
States / cities: Saraland, Alabama • Huntington Park, California • Lincoln, California + 32 more

Conditions: Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
Interventions: PTHrP (1-36); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 24 Years to 35 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Interventions: HIPEC, Carboplatin, Paclitaxel; Procedure · Drug
Lead sponsor: Andrea Jewell; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy
Interventions: Darifenacin, Tolterodine, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 21
States / cities: Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 18 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Class IV Angina
Interventions: Not listed
Lead sponsor: Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Acute Respiratory Failure
Interventions: Early ICU rehabilitation strategies, Usual Care; Other
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Gonorrhoea
Interventions: Meningococcal Group B Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Urea Cycle Disorder
Interventions: Not listed
Lead sponsor: Amgen; Industry
Eligibility: Not listed
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Blue Bell, Pennsylvania

Search by objective public record fields.

Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia

Hoosier Sport: Developing and Implementing a Sustainable Campus-Community Partnership in Rural Indiana

Allergy and Ashthma in Children Who Were Fed Supplemented Infant Formula

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

The Utility of a Novel Eye Shield With Reusable Adhesive Anchors for Post-operative Care After Ophthalmic Surgery

A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth

Intraabdominal Pressure Monitoring Urinary Catheter and Kidney Perfusion Pressure

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Patient-Reported Preferences Affecting Revascularization Decisions

Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.

The PEARL 8.0 Post-Approval Study

Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)